This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|December 2, 2014
- Pharmaceutical Technology-12-02-2014
- Volume 38
- Issue 12
Ross Planetary Mixers Increase Mixing Options
Ross’ Laboratory Double Planetary Mixers process a variety of applications including viscous pastes, putty-like materials, powder blends, and granulations. The mixers are designed with two identical blades that rotate on individual axes while revolving around the vessel on a common axis. The mixers can be used for mixing shear-sensitive gels, fragile glass spheres, fiber-filled mixtures, and abrasive compounds.
Designed for production from one-half pint to five gallons, the mixers are available in standard, heavy-duty, explosion-proof, and sanitary models. Options include sight/charge ports, video cameras, helical high velocity blades, heating and cooling jacket, sidewall thermowell, cove plug valve, built-in vacuum pump, discharge system, and touchscreen controls.
Ross, Charles & Son Company
Articles in this issue
almost 12 years ago
VIDEOJET Thermal Ink Printer Offers Increased Resolutionalmost 12 years ago
Sartorius Bioreactor and Microbial Fermenter Increases Efficiencyalmost 12 years ago
The Bio/Pharma Working Lifealmost 12 years ago
FDA Realigns Drug Inspection and Manufacturing Oversightalmost 12 years ago
Fitzpatrick Roll Compaction Series Improves Accuracyalmost 12 years ago
Drug Scandals Impact Industry in Japanalmost 12 years ago
Securing the Single-Use Supply Chainalmost 12 years ago
Improving Job Market Creates Opportunity for Changealmost 12 years ago
FDA Approves Novel Treatments in 2014almost 12 years ago
Novel Technologies Win CPhI Pharma AwardsRelated to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.